Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma

Howard Safran; Margaret Steinhoff; Shamlal Mangray; Ritesh Rathore; Thomas Charles King; Li Chai; Katya Berzein; Todd Moore; David Iannitti; Philip Reiss; Terese Pasquariello; Paul Akerman; Daniel Quirk; Robert Mass; Lisa Goldstein; Umadevi Tantravahi

doi:10.1097/00000421-200110000-00016

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma

Howard Safran, Margaret Steinhoff, Shamlal Mangray, Ritesh Rathore, Thomas Charles King, Li Chai, Katya Berzein, Todd Moore, David Iannitti, Philip Reiss, Terese Pasquariello, Paul Akerman, Daniel Quirk, Robert Mass, Lisa Goldstein, Umadevi Tantravahi

Research output: Contribution to journal › Article › peer-review

Abstract

Novel systemic treatments are needed in pancreatic cancer. The authors sought to establish the frequency of overexpression of the HER-2/neu oncogene in patients with pancreatic adenocarcinoma to determine the potential role of trastuzumab (Herceptin) as a therapeutic agent in this disease. Tumor specimens from patients with pancreatic adenocarcinoma were analyzed by staining for p185^HER2 protein using the DAKO immunohistochemical assay. Patients with and without HER-2/neu overexpression by immunohistochemistry were compared with respect to clinical and pathologic characteristics. HER-2/neu gene amplification was also evaluated by fluorescence in situ hybridization (FISH). Thirty-two of 154 patients (21%) had pancreatic adenocarcinoma that demonstrated HER-2/neu overexpression by immunohistochemistry. At initial diagnosis, 16% of resectable cancers, 17% of locally advanced cancers, and 26% of metastatic cancers were determined to have HER-2/neu overexpression. Three of 11 (27%) patients with HER-2/neu overexpression by immunohistochemistry had gene amplification by FISH. HER-2/neu overexpression occurs in a subset of pancreatic cancer. Evaluation of the efficacy of trastuzumab for patients with pancreatic cancer who overexpress HER-2/neu appears indicated.

Original language	English
Pages (from-to)	496-499
Number of pages	4
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	24
Issue number	5
DOIs	https://doi.org/10.1097/00000421-200110000-00016
State	Published - 2001
Externally published	Yes

Keywords

HER-2/neu
Pancreatic cancer
Trastuzumab

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00000421-200110000-00016

Cite this

Safran, H., Steinhoff, M., Mangray, S., Rathore, R., King, T. C., Chai, L., Berzein, K., Moore, T., Iannitti, D., Reiss, P., Pasquariello, T., Akerman, P., Quirk, D., Mass, R., Goldstein, L., & Tantravahi, U. (2001). Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 24(5), 496-499. https://doi.org/10.1097/00000421-200110000-00016

@article{dc27e69d9b69477486c0f59a6ce7a71a,

title = "Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma",

abstract = "Novel systemic treatments are needed in pancreatic cancer. The authors sought to establish the frequency of overexpression of the HER-2/neu oncogene in patients with pancreatic adenocarcinoma to determine the potential role of trastuzumab (Herceptin) as a therapeutic agent in this disease. Tumor specimens from patients with pancreatic adenocarcinoma were analyzed by staining for p185HER2 protein using the DAKO immunohistochemical assay. Patients with and without HER-2/neu overexpression by immunohistochemistry were compared with respect to clinical and pathologic characteristics. HER-2/neu gene amplification was also evaluated by fluorescence in situ hybridization (FISH). Thirty-two of 154 patients (21%) had pancreatic adenocarcinoma that demonstrated HER-2/neu overexpression by immunohistochemistry. At initial diagnosis, 16% of resectable cancers, 17% of locally advanced cancers, and 26% of metastatic cancers were determined to have HER-2/neu overexpression. Three of 11 (27%) patients with HER-2/neu overexpression by immunohistochemistry had gene amplification by FISH. HER-2/neu overexpression occurs in a subset of pancreatic cancer. Evaluation of the efficacy of trastuzumab for patients with pancreatic cancer who overexpress HER-2/neu appears indicated.",

keywords = "HER-2/neu, Pancreatic cancer, Trastuzumab",

author = "Howard Safran and Margaret Steinhoff and Shamlal Mangray and Ritesh Rathore and King, {Thomas Charles} and Li Chai and Katya Berzein and Todd Moore and David Iannitti and Philip Reiss and Terese Pasquariello and Paul Akerman and Daniel Quirk and Robert Mass and Lisa Goldstein and Umadevi Tantravahi",

year = "2001",

doi = "10.1097/00000421-200110000-00016",

language = "English",

volume = "24",

pages = "496--499",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "5",

}

Safran, H, Steinhoff, M, Mangray, S, Rathore, R, King, TC, Chai, L, Berzein, K, Moore, T, Iannitti, D, Reiss, P, Pasquariello, T, Akerman, P, Quirk, D, Mass, R, Goldstein, L & Tantravahi, U 2001, 'Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 24, no. 5, pp. 496-499. https://doi.org/10.1097/00000421-200110000-00016

TY - JOUR

T1 - Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma

AU - Safran, Howard

AU - Steinhoff, Margaret

AU - Mangray, Shamlal

AU - Rathore, Ritesh

AU - King, Thomas Charles

AU - Chai, Li

AU - Berzein, Katya

AU - Moore, Todd

AU - Iannitti, David

AU - Reiss, Philip

AU - Pasquariello, Terese

AU - Akerman, Paul

AU - Quirk, Daniel

AU - Mass, Robert

AU - Goldstein, Lisa

AU - Tantravahi, Umadevi

PY - 2001

Y1 - 2001

N2 - Novel systemic treatments are needed in pancreatic cancer. The authors sought to establish the frequency of overexpression of the HER-2/neu oncogene in patients with pancreatic adenocarcinoma to determine the potential role of trastuzumab (Herceptin) as a therapeutic agent in this disease. Tumor specimens from patients with pancreatic adenocarcinoma were analyzed by staining for p185HER2 protein using the DAKO immunohistochemical assay. Patients with and without HER-2/neu overexpression by immunohistochemistry were compared with respect to clinical and pathologic characteristics. HER-2/neu gene amplification was also evaluated by fluorescence in situ hybridization (FISH). Thirty-two of 154 patients (21%) had pancreatic adenocarcinoma that demonstrated HER-2/neu overexpression by immunohistochemistry. At initial diagnosis, 16% of resectable cancers, 17% of locally advanced cancers, and 26% of metastatic cancers were determined to have HER-2/neu overexpression. Three of 11 (27%) patients with HER-2/neu overexpression by immunohistochemistry had gene amplification by FISH. HER-2/neu overexpression occurs in a subset of pancreatic cancer. Evaluation of the efficacy of trastuzumab for patients with pancreatic cancer who overexpress HER-2/neu appears indicated.

AB - Novel systemic treatments are needed in pancreatic cancer. The authors sought to establish the frequency of overexpression of the HER-2/neu oncogene in patients with pancreatic adenocarcinoma to determine the potential role of trastuzumab (Herceptin) as a therapeutic agent in this disease. Tumor specimens from patients with pancreatic adenocarcinoma were analyzed by staining for p185HER2 protein using the DAKO immunohistochemical assay. Patients with and without HER-2/neu overexpression by immunohistochemistry were compared with respect to clinical and pathologic characteristics. HER-2/neu gene amplification was also evaluated by fluorescence in situ hybridization (FISH). Thirty-two of 154 patients (21%) had pancreatic adenocarcinoma that demonstrated HER-2/neu overexpression by immunohistochemistry. At initial diagnosis, 16% of resectable cancers, 17% of locally advanced cancers, and 26% of metastatic cancers were determined to have HER-2/neu overexpression. Three of 11 (27%) patients with HER-2/neu overexpression by immunohistochemistry had gene amplification by FISH. HER-2/neu overexpression occurs in a subset of pancreatic cancer. Evaluation of the efficacy of trastuzumab for patients with pancreatic cancer who overexpress HER-2/neu appears indicated.

KW - HER-2/neu

KW - Pancreatic cancer

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=0034793404&partnerID=8YFLogxK

U2 - 10.1097/00000421-200110000-00016

DO - 10.1097/00000421-200110000-00016

M3 - Article

C2 - 11586103

AN - SCOPUS:0034793404

SN - 0277-3732

VL - 24

SP - 496

EP - 499

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 5

ER -

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this